|

KN026 Clinical Trials

3 actively recruiting trials

No change since June 2026

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Shanghai JMT-Bio Inc.1
  • Peking University1
  • CSPC Megalith Biopharmaceutical Co.,Ltd.1

Indications

  • Cancer3
  • Breast Cancer2
  • Resectable HER2-positive Breast Cancer1
  • HER2-positive Locally Advanced Resectable Gastric Cancer1
  • Advanced Breast Cancer1

Other3 trials

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
Phase 2
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.